Dup15q Syndrome - Market Insights, Epidemiology & Forecasts to 2030 - ResearchAndMarkets.com

DUBLIN--()--The "Dup15q Syndrome - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Dup15q syndrome, historical and forecasted epidemiology as well as the Dup15q syndrome market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Dup15q syndrome market size from 2017 to 2030. The report also covers current Dup15q syndrome treatment practices, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Dup15q Syndrome, Total Diagnosed Prevalent Population of Dup15q Syndrome, and Type-specific Diagnosed Prevalent Population of Dup15q Syndrome scenario of Dup15q syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

  • Total prevalent cases of Dup15q syndrome in the 7MM was found to be 45,884 in 2017.
  • Total prevalent cases of Dup15q syndrome in the US were found to be 22,077 in 2017.
  • Total diagnosed prevalent cases of Dup15q syndrome in the US were found to be 4,415 in 2017.
  • Among the European 5 countries, Germany had the highest diagnosed population of Dup15q syndrome with 793 cases, followed by the United Kingdom and Italy respectively. On the other hand, Spain had the lowest population of 323 cases in 2017.
  • In 2017, out of the total diagnosed cases (4,415) in the US for Dup15q syndrome, 2,649 cases and 1,766 cases were contributed by idic (15) and int dup (15), respectively.
  • Japan had 8,374 prevalent cases of Dup15q syndrome in 2017. Out, of these cases, approximately 20% were the diagnosed population.

Drug Chapters

The drug chapter segment of the Dup15q syndrome report encloses the detailed analysis of Dup15q syndrome pipeline drugs. It also helps to understand the Dup15q syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, and patent details of included drug and the latest news and press releases.

Emerging Drugs

Soticlestat (OV935/TAK-935): Ovid Therapeutics/Takeda

Soticlestat, previously called TAK-935 or OV935, is an investigational treatment developed by Takeda Pharmaceuticals in collaboration with Ovid Therapeutics to treat rare developmental and epileptic encephalopathies (DEE). It is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control, and have an oral route of administration.

Soticlestat inhibits the activity of an enzyme called cholesterol 24-hydroxylase (CH24H), which is found at high levels in the brain where it plays a role in cholesterol metabolism. Research has shown that it is also involved in regulating a neurotransmitter or cell-signaling molecule called glutamate. One of the main neurotransmitters in the brain is glutamate that can increase the initiation and spread of seizure activity. High levels of CH24H activate glutamate signaling pathways, so by inhibiting CH24H, Soticlestat should be able to reduce the number and severity of seizures. As per Ovid, Soticlestat is the only molecule with this mechanism of action in clinical development as an anti-epileptic drug (AED).

Market Outlook

Most of the patients suffering from the Dup15q syndrome show a variety of symptoms, and the current treatment approach helps in managing them. The choice of treatment to be adopted depends on the type of symptoms the person is showing.

A study was conducted to examine the phenotypes and treatments of seizures in Dup15q in a large population. In the study, ~400 families were contacted through the Dup15q Alliance and asked to complete a questionnaire survey online regarding the presence and presentation of epilepsy in their family member with a chromosome 15q duplication. There were responses from 95 family members of individuals with chromosome 15q duplications, representing a response rate of ~25% of the entire Dup15q Alliance in 2009.

For the 22 children with infantile spasms, the most common first and second medications used were adrenocorticotropic hormone (ACTH)/prednisone (5, first; 7, second) and vigabatrin (VGB; 5, first; 2, second), with the only other medications used by more than one respondent being valproic acid (VPA, 2) and topiramate (TPM, 2). ACTH/prednisone was more effective than VGB in controlling seizures (75% vs. 29% with >90% seizure reduction for those that tried each medication) with similar rates of seizure exacerbation. For all other seizure types, there was an overall 24% response rate to the first medication prescribed, with an additional 21% showing 50-90% seizure improvement (61%). For the second medication prescribed (45%), there was a 36% response rate. The most commonly prescribed medications were VPA (60%), levetiracetam (LEV, 44%), TPM (40%), lamotrigine (LTG, 37%), carbamazepine (CBZ, 35%), zonisamide (ZNS, 23%), and clonazepam (CLZ, 23%). Family members believed that the most effective medications for controlling seizures were the following: rufinamide (RUF; 12%), CBZ (35%), LTG (37%), oxcarbazepine (OXC; 12%), and VPA (60%). Overall, only 1 (< 5%) of 22 of those who tried a benzodiazepine indicated that it was the most effective medication. The percentage of those still taking each medication at the time of the study was highest in broad-spectrum AED such as RUF (12%), LTG (37%), VPA (60%), and ZNS (23%). Intolerable adverse effects were reported most frequently in those taking LEV (52%, most common behavioral), ZNS (50%, sedation), clobazam (CLB; 50%, sedation), OXC (50%, sedation), and TPM (48%, sedation). Only a few respondents had family members who tried nonpharmacologic treatments including the ketogenic diet (2%), vagus nerve stimulation (13%), gluten-free diet (2%), and surgical resection (2%) (Conant et al., 2014).

The Dup15q syndrome has received little attention because of its rarity, the fairly nonspecific phenotype, the clinical heterogeneity, and the wide spectrum of severity. Along with developmental delay, ASD and epilepsy are predominant components of the clinical picture. In a retrospective cohort of 30 unrelated patients, 77% of cases met the criteria for developmental delay, while 74% had a diagnosis of ASD.

So far there is no approved therapy for the treatment of the disease and the present management options provide symptomatic treatment. In the developmental pipeline, one therapy is there that is under investigation for Dup15q syndrome.

Key Findings

  • The market size of Dup15q syndrome in the 7MM was USD 15.69 million in 2017.
  • The market size of Dup15q syndrome in the US was USD 8.94 million in 2017.
  • In 2017, among the EU-5 countries, Germany had the highest market size of USD 1.12 million, followed by the United Kingdom, and Italy. The lowest market size was estimated in Spain with USD 0.46 million in 2017.
  • Till now, there are no approved therapies for the disease. The treatment available provides supportive/symptomatic management. Additionally, not many companies are investigating this therapeutic area, hence there is only one therapy that is expected to be launched in the forecasted period (2020-2030).
  • Soticlestat (OV935/TAK-935) is expected to be launched in 2024 in the US, and 2025 in EU-5 and Japan. The molecule is anticipated to be approved as adjuvant therapy, hence its approval will not affect the market size of supportive therapies, and the market size of these therapies will continue to increase throughout the study period.
  • In the year 2017, the market size of supportive/symptomatic treatment was observed to be USD 15.69 million in the 7MM.
  • The market size of Japan in 2017 was observed at USD 2.37 million.

Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Dup15q syndrome market or expected to get launched in the market during the study period 2017-2030. The analysis covers the Dup15q syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Development Activities

The report provides insights into different therapeutic candidates in the phase II clinical stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Dup15q syndrome emerging therapies.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the Dup15q syndrome market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Dup15q syndrome, explaining its signs and symptoms, genes associated with the disease and currently available therapies.
  • Comprehensive insight has been provided into the Dup15q syndrome epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Dup15q syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Dup15q syndrome market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Dup15q syndrome market.

Report Highlights

  • The increasing prevalence of the disease along with promising emerging pipeline therapies will positively drive the Dup15q syndrome market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dup15q syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Dup15q syndrome. Launch of emerging therapy will significantly impact the Dup15q syndrome market.
  • In-depth analysis of the pipeline assets across different stages of development, different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ebri5k


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900